

RESEARCH ARTICLE

**Formulation and In- Vitro  
Evaluation of Tolperisone HCl  
Buoyant Tablet**

**Meman Asfak\*, Patel M.R., Patel K.R., Patel A.D.**

Department of Pharmaceutics,  
Shri B.M. Shah College of Pharmaceutical  
Education and Research

**Correspondence**

Asfak Meman  
Department of Pharmaceutics,  
Shri B.M. Shah College of  
Pharmaceutical education &  
research, Modasa Gujarat,  
India. E-mail:  
memon\_asfak@yahoo.in

**Keywords**

Tolperisone HCl, Buoyant  
tablet, Xanthan Gum, 3<sup>2</sup>  
full factorial design

**Received**

05/03/2014

**Reviewed**

09/03/2014

**Accepted**

14/03/2014

**ABSTRACT**

The aim of present investigation was undertaken with the objective of formulating buoyant tablet of Tolperisone HCl. Tolperisone HCl is a skeletal muscle relaxant. Drug is more stable in acidic medium (pH < 4.5), and in alkaline medium (pH 4 to 7) tolperisone breaks down into 4-MMPPO [2methyl-1-(4methylphenyl)-propanone] and piperidine. Thus, the patient is exposed to an uncontrollable quantity of genotoxic agent 4-MMPPO. 3<sup>2</sup> full factorial designs were used for optimization of formulation variable. The drug: polymer ratio (X1) and concentration of sodium bicarbonate (X2) were selected as independent variables, while time required for drug release 50% (t50), time required for drug release 90% (t90), drug release at 12hr (Q12), Floating lag time, release rate constant (k) and diffusion exponent (n) were selected as a dependent variable. Prepared tablets were evaluated for pre compression and post compression parameters. The release mechanisms were explored and explained by applying zero order, first order, and Higuchi and Korsmeyer equations. Regression analysis and analysis of variance were performed for dependent variables. Optimized formulation (B6) showed 99.27% drug release at the end of 24 hrs and maximum similarity factor (f2= 74.41) and minimum dissimilarity factor (f1= 4.24) with theoretical release profile of Tolperisone HCl. Optimized formulation followed by anomalous nonFickian release mechanism and found to be stable after 21 days at accelerated condition.

## INTRODUCTION

The gastro retentive drug delivery system can be retained in the stomach and assist in improving the oral control delivery of drug that have an absorption window in a particular region of the gastrointestinal tract. This system helps in continuously releasing the drug, thus ensuring optimal bioavailability. The matrix tablet composed of drug and the release retarding material offers the simplest approach in designing of control release system. Skeletal muscle relaxants are drug that acts peripherally at neuromuscular junction or muscle fibre itself or centrally in the cerebrospinal axis to reduce the muscle tone. Centrally acting muscle relaxants are used mainly for painful muscle spasm and spastic neurological condition (1). Tolperisone HCl causes muscle relaxation by its action on central nervous system. It also leads to membrane stabilizer and has analgesic activity. It has also been used in treatment of condition which includes dysmenorrhoea, climacteric complaints, lockjaw, and neurolyticism. Tolperisone HCl is a "Class-I" drug according to Bio-pharmaceutics Classification System, possessing both high solubility and high permeability absorption characteristics. Tolperisone HCl is rapidly

and completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 0.9-1.0 hours after oral dosing. Tolperisone HCl breaks down into 4-MMPPO [2 Methyl-1-(4-methyl phenyl)-propanone] and piperidine hydrochloride when undergoes into intestinal pH at 4 to 7. Thus the patient is exposed to an uncontrollable quantity of 4-MMPPO which causes genotoxicity. This problem is overcome by controlled release of tolperisone hydrochloride in the stomach at pH 1 to 2 (2). Tolperisone HCl has a short biological half life (1.5 - 2.5hr). If it is formulated as conventional tablet it will require 150mg -450mg (2-3 times daily) in divided dosage. So it makes the tolperisone hydrochloride an ideal candidate for the control drug delivery (3).

## MATERIALS

Tolperisone, Xanthan, Gum, Guar Gum and Dibasic calcium phosphate (DCP), Sodium bicarbonate, Magnesium stearate, Talc.

## METHOD

### Preparation of Tolperisone HCl Buoyant Tablets

#### Method: Direct Compression

Direct compression was followed to manufacture the gas generating buoyant tablets of Tolperisone HCl. All the ingredients were accurately weighed and

pass through sieve no. 60 before using into formulation. Compressed on 10 station rotary tablet machine using caplet punch. The tablets were compressed to obtain hardness in a range of 6-7 Kg/cm<sup>2</sup>.

### **Evaluation of Powder Blend and Tablets**

#### **Drug-Excipients Compatibility study**

Fourier transform infrared spectroscopy has been used to study the physical and chemical interaction between drug and the excipients used. Fourier transform infrared (FTIR) spectra of Tolperisone hydrochloride, Xanthan Gum were recorded using KBr mixing method.

#### **Loose Bulk Density**

Weigh accurately 5 gm of powder blend, and transferred in 100 ml graduated cylinder. Carefully level the powder blend without tcompacting, and read the unsettled apparent volume (V<sub>0</sub>). Calculate the apparent bulk density in gm/ml by the following formula:

Bulk Density = Mass/ apparent volume

#### **Tapped Bulk Density**

Weigh accurately 5 gm of powder blend, and transferred in 100 ml graduated cylinder. Then mechanically tap the cylinder containing the sample by raising the cylinder and allowing it to drop under its own weight using mechanically tapped density tester that provides a fixed drop of 14±2 mm at a nominal rate of 300 drops per minute. Tap

the cylinder for 500 times initially and measure the tapped volume (V<sub>1</sub>) to the nearest graduated units, repeat the tapping an additional 750 times and measure the tapped volume (V<sub>2</sub>) to the nearest graduated units, if the difference between the two volumes is less than 2% then final the volume (V<sub>2</sub>). Calculate the tapped bulk density in gm/ml by the following formula:

Tapped Density = Mass/ tapped volume

#### **Carr's Index**

The Compressibility Index of the powder blend was determined by Carr's compressibility index. It is a simple test to evaluate the Bulk Density and Tapped Density of a powder blend and the rate at which it packed down. The formula for Carr's Index is as below:

Carr's Index = Tapped Density-Bulk Density×100/ Tapped Density

#### **Hausner's Ratio**

The Hausner's ratio is a number that is correlated to the flowability of a powder blend material. Hausner's Ratio = Tapped Density/Bulk Density

#### **Angle of Repose**

The angle of repose of powder blend powder was determined by the funnel method. The diameter of the powder blend cone was measured and angle of repose was calculated using the following Equ. Angle of Repose

$$(\theta) = \tan^{-1}h/r$$

Where, h =Height of the powder blend cone

r =Radius of the powder blend cone

### **Weight Variation Test**

The 20 tablets were selected at random, weighed and the average weight was calculated. Not more than two of the individual weights should deviate from the average weight by more than 10%.

### **Friability**

For each formulation, pre weighed tablet sample (10 tablets) were placed in the Roche friabilator which is then operated for 100 revolutions. The tablets were deducted and re-weighed. Conventional compressed tablets that loose <0.5 to 1% of their weight are considered acceptable.

### **Hardness**

Hardness of tablet was determined using Monsanto hardness tester.

### **Content Uniformity**

The 20 tablets were crushed and the powder equivalent of 100mg of drug was transferred to 100ml of 0.1N HCl in volumetric flask. The solution was analyzed at 261 nm using double beam UV-Vis spectrophotometer after suitable dilution. The content of drug was calculated from calibration curve.

### ***In-vitro* buoyancy study**

The *In-vitro* buoyancy was characterized by floating lag time (FLT) and total floating

time (TFT). The test was performed using USP24 type II paddle apparatus using 900 ml of 0.1 N HCl at 50 rpm at  $37 \pm 0.5^\circ\text{C}$ . The time required for tablet to rise to surface of dissolution medium and duration of time the tablet constantly float on dissolution medium were noted as FLT and TFT, respectively (4-10).

### ***In vitro* drug release study**

The *In vitro* drug release was performed using USP-24 type II paddle apparatus in 900 ml of 0.1N HCl at 50 rpm at  $37 \pm 0.5^\circ\text{C}$ . The samples were withdrawn at pre-determined time intervals for period of 24 hr and replaced with the fresh medium. The samples were filtered through  $0.45\mu\text{m}$  membrane filter suitably diluted and analyzed at 261 nm using double beam UV-Vis spectrophotometer. The content of drug was calculated using calibration curve.

### **Kinetic model for release data**

The drug released data of all batches were fitted with desired kinetic model such as Zero order kinetic, First order kinetic, Higuchi model and Korse meyer peppas model to ascertain the drug release. The Zero order and First order drug release. The Zero order and First order drug release explain the drug release depend on drug concentration or not. The Korse meyer peppas model described the method of drug

release and Higuchi model described the diffusional drug release.

$$\text{Zero order} = Q_t = Q_0 + K_0t$$

$$\text{First order} = Q_t = Q_0e^{-K_1t}$$

$$\text{Higuchi model} = m = (100-q) \times t^{1/2}$$

$$\text{Hixon Crowell Model} = W_0^{1/3} - W_t^{1/3} = kt$$

$$\text{Korsmeyer peppas model} = Mt/M\alpha = K \times t^n$$

Where  $Q_t$  is the amount of drug dissolved in time  $t$ ,  $Q_0$  is the initial amount of drug in the solution,  $Q_t$  is the amount of drug dissolved in time  $t$ ,  $W_0$  is initial amount of drug in dosage form,  $W_t$  is remaining amount of drug in dosage form at time  $t$ ,  $Mt/M\alpha$  is the fraction of drug release at time  $t$  and  $n$  is diffusion exponent.  $K_0, K_1$ , and  $k$  refer to the rate constant (11-14).

### Statistical analysis

The statistical analysis of the factorial design batches was performed by multiple regression analysis using Microsoft Excel. Polynomial models were generated for all the response variables using Microsoft Excel. In addition analysis of variance (ANOVA) was used to identify significant effects of factors on response regression coefficients. The F value and p values were also calculated using Microsoft Excel. The relationship between the dependent and independent variables was further elucidated using response surface plots.

### Similarity factor ( $f_2$ )

To evaluate and comparison of dissolution profiles, the dissolution profiles were analyzed using similarity factor  $f_2$ . The  $f_2$  value between 50 and 100 suggests that the dissolution profiles are similar. The  $f_2$  value of 100 suggests that the dissolution profiles are similar. The  $f_2$  value of 100 suggests that the test and reference profiles are identical and as the value becomes smaller, the dissimilarity between releases profile increases.

### Dissimilarity factor ( $f_1$ )

The dissimilarity factor ( $f_1$ ) calculates the percent difference between the two curves at each time point and is a measurement of the relative error between the two curves. The values should lie between 0-15. For curves to be considered similar  $f_1$  values should be close to 0.

### Accelerated stability study

A variety of environmental factor such as temperature, humidity, and light, and to establish a re-test for the drug substance or a shelf life for the drug product and recommended storage condition. The storage condition used for stability studies were accelerated condition ( $40^\circ\text{C} \pm 2^\circ\text{C} / 75\% \pm 5\% \text{RH}$ ). Stability study was carried out for the optimized formulations. Tablets of optimized formulation were striped packed

and kept in humidity chamber on above mention temperature (15).

## RESULT AND DISCUSSION

the drug and polymer were compatible with each other. The powder mixture used for tablet preparation were evaluated for pre-compression parameter like bulk density, tapped density, Hausner's ratio, Carr's index, and angle of repose, are shown in table 2. Tolperisone HCl floating tablets were prepared and evaluated for hardness, friability and drug content uniformity. The results are shown in the table 3. From the dissolution profile it was observed that there was significant outcome of different polymers and polymer load on drug release. All batches exhibit initial burst release of drug due to rapid dissolution of drug from tablet surface. The kinetics of the dissolution data were well fitted to zero order, Higuchi model and Korsmeyer-Peppas model as evident from regression coefficients (Table 9). The values of Dissimilarity factor ( $f_1$ ) for batches B1, B2, B3, and B6 were less than 15 compared with theoretical dissolution profile (Table 10) indicating good similarity in dissolution (Table 10). The batch B6 showed minimum value of  $f_1$  (4.24). The values of similarity factor ( $f_2$ ) for batches B1, B2, B3, and B6 were greater than 50 compared with theoretical dissolution profile (Table 10)

indicating good similarity in dissolution (Table 10). The batch B6 showed maximum value of  $f_2$  (74.41).

## CONCLUSION

The present investigation was aimed to formulate and evaluate floating tablet of Tolperisone HCl were prepared by direct compression method based on natural polymers (e.g. Xanthan Gum and Guar Gum) as matrix forming material and different concentration of sodium bicarbonate as gas generating agents. FTIR spectroscopy indicates that the drug is compatible with the polymer. The concentration of Xanthan Gum and sodium bicarbonate were successfully optimized by using  $3^2$  factorial design. From the  $3^2$  factorial design and different graphical representation, it was finalized that batch B6 was found to be optimized batch having drug release up to 24 hr. Moreover, the dissolution profile of optimized batch B6 was found to be similar with theoretical drug release profile having similarity factor more than 50 ( $f_2=74.41$ ) and dissimilarity factor less than 15 ( $f_1=4.24$ ) which reflects the feasibility of the optimization procedure in successful development of floating matrix tablet containing Tolperisone HCl by using Xanthan Gum. Various kinetic models confirmed that *in vitro* release kinetic of

optimized formulation (B6) was best fitted into zero order model and Higuchi with anomalous non Fickian release mechanism. The optimized batch was found to be stable after 21 days at accelerated condition.

## REFERENCES

1. Tripathi KD. 2006. Essential of Medical Pharmacology; 6th Edn; Jaypee Brothers Medical Publisher LTD, pp339.
2. Welzig s, Rothenburger J, Kalz B, Gungl J, Gerdes K. 2007. Tolperisone hydrochloride controlled release tablet. United State Patents USP 20100249423.
3. Chatwal GR., Anand SK, 2002. Instrumental Method of Chemical Analysis; 5thEdn; Himalaya Publishing House, 82, pp 29-30.
4. Flese EF., Huguen TA., and Lachman L.1987. In Preformulation; The theory and Practice of Industrial Pharmacy; 4th Edn; Varghese Publishing House, Mumbai, pp 171.
5. Wells JI.Aulton ME, 2002. In Preformulation; Pharmaceutics the Science of Dosage Form Design; 2nd Edn; Churchill Livingstone, pp 223.
6. Cooper J, Gun C, Carter SJ, 1986. In Powder Flow and Compaction; Tutorial Pharmacy; CBS Publishers and Distributors, pp 211.
7. MartinA, 1997. In Micromeretics; Physical Pharmacy; 4<sup>th</sup>Edn; B.I.Waverly Pvt. Limited, pp 423.
8. Indian Pharmacopoeia, 2010. Volume I, TheIndian Pharmacopoeia Commission, Ghaziabad, India, 6thEdn. 192-193.
9. Patel V F, Patel N M, Yeole P G, 2005. Studies on formulation and evaluation ranitidine floating tablets. *Ind. J. Pharm. Sci.*, 67(6), 703-709.
10. Coasta P, Manuel J, Labao S. 2002. Modelling and comparison of dissolution profiles. *Euro. J. Pharma. Sci.*, 13, 123-133.
11. Higuchi T, 1961. Rate of release of medicament from ointment bases containing drugs in suspension. *J. Pharm. Sci.* 50, 874.
12. Hixon A W, Crowell J H, 1931. Dependence of reaction velocity upon surface and agitation theoretical consideration. *Ind. Eng. Chem.*, 23, 923.
13. Korsemeyer RW, Ginnu R, Doelker E, Buri P, Peppas NA, 1983. " Mechanism of solute release from porous hydrophilic polymers. *J. Pharm.*, 15, 25.
14. Costa P, 2001. An alternative method to evaluation of similarity factor in dissolution testing. *Int. J. Pharm.*, 220. 77-83.
15. Moore J W, Flanner H H, 1996. Mathematical comparison of




dissolution profiles. *Pharm.Technol.*,  
20(6), 67-74.

## EXPERIEMNTAL RESULT DATA

**Table 1: Composition of Preliminary Batches**

FORMULATION INGREDIENT (mg)	FORMULATION BATCH CODE							
	F1	F2	F3	F4	F5	F6	F7	F8
Tolperisone HCl	150	150	150	150	150	150	150	150
Xanthan Gum	150	300	450	600	-	-	-	-
Guar Gum	-	-	-	-	150	300	450	600
NaHCO <sub>3</sub>	90	90	90	90	90	90	90	90
DCP	495	345	195	45	495	345	195	45
Mg. Stearate	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5
Talc	7.5	7.5	7.5	7.5	7.5	7.5	7.5	7.5
Total weight	900	900	900	900	900	900	900	900





**Figure 1: FTIR spectrum of Tolperisone HCl formulation**

**Table 2: Pre-Compression evaluation parameter of trial batches**

<b>Batch code</b>	<b>Bulk density ( gm/ml)</b>	<b>Tapped density ( gm/ml)</b>	<b>Hausner's Ratio</b>	<b>Carr's Index (%)</b>	<b>Angle of repose (Θ)</b>
<b>F1</b>	0.384	0.438	1.14	12.32	27.82
<b>F2</b>	0.39	0.450	1.15	13.33	27.75
<b>F3</b>	0.370	0.413	1.11	10.41	29.42
<b>F4</b>	0.37	0.416	1.12	11.05	29.57
<b>F5</b>	0.362	0.413	1.14	12.34	28.73
<b>F6</b>	0.35	0.396	1.13	11.61	29.93
<b>F7</b>	0.36	0.40	1.12	10	27.89
<b>F8</b>	0.36	0.413	1.14	12.83	27.21

**Table 3: Post compression evaluation parameter of trial batches**

Batch	Weight variation (mg) ± S.D (n=20)	Hardness* (Kg/cm <sup>2</sup> ) ± S.D	Friability (%)	Content uniformity* (%) ± S.D	Buoyancy	
					FLT (sec)	TFT (Hr)
F1	910±1.44	6.7±0.20	0.62	97.6±0.48	148	>24
F2	885±1.39	6.9±0.18	0.52	102±0.10	185	>24
F3	887±1.53	6.7±0.14	0.58	99.6±0.23	214	>24
F4	898±1.34	6.8±0.15	0.68	98.3±0.62	239	>24
F5	882±1.12	6.8±0.22	0.60	97.6±0.26	182	>24
F6	896±1.47	6.6±0.11	0.58	99.2±0.34	230	>24
F7	904±1.63	6.8±0.18	0.57	103.4±0.42	244	>24
F8	893±1.78	6.7±0.17	0.52	100.2±0.18	277	>24

**Table 4: Experimental design: Independent and dependent variables**

<b>3<sup>2</sup> full factorial design</b>			
	Independent variables		Dependent variables
Coded value	X1 (Concentration of Xanthan Gum)	X2 (concentration of NaHCO <sub>3</sub> )	Response (Y)
-1	1:2.5	5%	t <sub>50</sub> , t <sub>90</sub> , Q <sub>12</sub> , floating lag time, diffusion coefficient (n) and release rate constant (k)
0	1:3	10%	
+1	1:3.5	15%	

**Table 5: Formulation of factorial design batches tablets**

Ingredients (mg)	FORMULATION BATCH CODE								
	B1	B2	B3	B4	B5	B6	B7	B8	B9
Tolperisone HCl	150	150	150	150	150	150	150	150	150
Xanthan Gum	375	450	525	375	450	525	375	450	525
DCP	267	192	117	224	149	74	182	107	32
NaHCO <sub>3</sub>	42	42	42	85	85	85	127	127	127
Mg. Stearate	8	8	8	8	8	8	8	8	8
Talc	8	8	8	8	8	8	8	8	8
Total Weight	850	850	850	850	850	850	850	850	850

**Table 6:Pre-Compression parameters of factorial batches**

Batch code	Bulk density ( gm/ml)	Tapped density ( gm/ml)	Hausner's Ratio	Carr's Index (%)	Angle of repose (Θ)
B1	0.476	0.531	1.11	11.32	27.01
B2	0.485	0.546	1.12	11.23	24.83
B3	0.492	0.564	1.14	12.79	28.36
B4	0.480	0.540	1.12	11.11	29.57
B5	0.481	0.550	1.14	12.72	27.02
B6	0.495	0.564	1.14	12.23	23.02
B7	0.490	0.550	1.13	10.90	24.77
B8	0.500	0.568	1.13	11.97	26.11
B9	0.497	0.578	1.16	16.29	25.14


**Table 7: Post compression evaluation parameter of factorial batches**

Batch	Weight	Hardness*	Friability	Content	Buoyancy


	<b>variation</b> <b>(mg) ± S.D</b> <b>(n=20)</b>	<b>(Kg/cm<sup>2</sup>)</b> <b>±S.D</b>	<b>(%)</b>	<b>uniformity*</b> <b>(%) ±S.D</b>	<b>FLT</b> <b>(sec)</b>	<b>TFT (Hr)</b>
<b>B1</b>	827±1.35	6.6±0.17	0.79	96.72±0.22	557	>24
<b>B2</b>	845±1.19	6.8±0.13	0.73	98.23±0.18	814	>24
<b>B3</b>	859±1.28	6.8±0.14	0.64	98.48±0.36	1189	>24
<b>B4</b>	844±1.15	6.7±0.23	0.76	99.45±0.27	231	>24
<b>B5</b>	835±1.26	6.6±0.14	0.69	99.93±0.17	264	>24
<b>B6</b>	853±1.26	6.7±0.21	0.61	99.89±0.09	267	>24
<b>B7</b>	839±1.74	6.8±0.12	0.74	98.68±0.29	178	>24
<b>B8</b>	841±1.24	6.6±0.15	0.67	100.82±0.25	212	>24
<b>B9</b>	860±1.19	6.8±0.19	0.58	100.43±0.12	236	>24

**Result of *In-Vitro* drug release of trial batches**

The results of *in vitro* drug release study are depicted in figure 2 and 3.




**Figure 2: In-vitro Drug release studies of preliminary batches of F1 to F4**




**Result of *In-Vitro* drug release of factorial batches**


The results of *in vitro* drug release study are depicted in figure 4, 5 and 6.



**Figure 4: In-vitro Drug release studies of factorial batches of B1, B4 and B7**



**Figure 5: In-vitro Drug release studies of factorial batches of B2, B5 and B8**



**Figure 6: In-vitro Drug release studies of factorial batches of B3, B6 and B9**

**Result of statistical analysis of factorial batches**

**Table 8: Result of dependent variables**

Batch code	Variable levels		t <sub>50</sub>	t <sub>90</sub>	Q <sub>12</sub>	Floating lag time (FLT)	n	k
	X1	X2						
B1	-1	-1	10.05	21.34	56.89	557	0.622	0.126
B2	0	-1	11.35	23.12	52.2	814	0.654	0.107
B3	1	-1	12.22	24.5	49.26	1189	0.704	0.088
B4	-1	0	7	16.61	70.79	231	0.571	0.175
B5	0	0	7.61	18.46	66.17	264	0.591	0.159
B6	1	0	10.07	21.5	56.74	267	0.609	0.130
B7	-1	1	3.76	10.81	96.75	178	0.550	0.245
B8	0	1	4.26	11.89	92.75	212	0.562	0.231
B9	1	1	5.66	13.31	83.14	236	0.606	0.185


**Full and reduced model for t<sub>50</sub> (hr)**

$$Y1 = 7.968 + 1.19(X_1) - 3.323(X_2) + 0.386(X_1X_1) - 0.343(X_2X_2) - 0.0675(X_1X_2)$$

**Summary of results of regression analysis for t<sub>50</sub> (hr)**

Response t <sub>50</sub> (hr)	b <sub>0</sub>	b <sub>1</sub>	b <sub>2</sub>	b <sub>11</sub>	b <sub>22</sub>	b <sub>12</sub>	R <sup>2</sup>	P
FM	7.968	1.19	-3.32	0.386	-0.343	-0.067	0.989	0.0035
p Value	0.0002	0.0108	0.0005	0.3658	0.4149	0.8100	-	-
RM	7.997	1.19	-3.32	-	-	-	0.982	5.55E-06






**Figure 7: Response surface plot for  $t_{50}$**

**Full and reduced model for  $t_{90}$  (hr)**

$$Y_1 = 18.731 + 1.758(X_1) - 5.491(X_2) + 0.188(X_1X_1) - 1.361(X_2X_2) - 0.165(X_1X_2)$$

**Summary of results of regression analysis for  $t_{90}$  (hr)**

<b>Response <math>t_{90}</math> (hr)</b>	<b><math>b_0</math></b>	<b><math>b_1</math></b>	<b><math>b_2</math></b>	<b><math>b_{11}</math></b>	<b><math>b_{22}</math></b>	<b><math>b_{12}</math></b>	<b><math>R^2</math></b>	<b>p</b>
<b>FM</b>	18.731	1.758	-5.491	0.188	-1.361	-0.165	0.992	0.00238
<b>p Value</b>	5.53E-05	0.0099	0.0003	0.7414	0.0792	0.684	-	-
<b>RM</b>	17.948	1.758	-5.491	-	-	-	0.973	1.95E-05




**Figure 8: Response surface plot for  $t_{90}$   
Full and reduced model for  $Q_{12}$  (%)**

$$Y_1 = 65.53 - 5.881(X_1) + 19.048(X_2) - 1.445(X_1X_1) + 7.265(X_2X_2) - 1.495(X_1X_2)$$

**Summary of results of regression analysis for  $Q_{12}$  (%)**

Response $Q_{12}$ (%)	$b_0$	$b_1$	$b_2$	$b_{11}$	$b_{22}$	$b_{12}$	$R^2$	P
<b>FM</b>	65.53	-5.881	19.048	-1.445	7.265	-1.495	0.996	0.0007
<b>p Value</b>	1.79E-05	0.0038	0.0001	0.3310	0.0101	0.1890	-	-
<b>RM</b>	64.566	-5.88	19.048	-	7.265	-	0.991	1.54E-05




**Figure 9: Response surface plot for Q<sub>12</sub>**

**Full and reduced model for Floating lag time (sec)**

$$Y_1 = 245.33 + 121(X_1) - 322.33(X_2) + 13(X_1X_1) + 277(X_2X_2) - 143.5(X_1X_2)$$

**Summary of results of regression analysis for Floating lag time (sec)**

<b>Response FLT (sec)</b>	<b>b<sub>0</sub></b>	<b>b<sub>1</sub></b>	<b>b<sub>2</sub></b>	<b>b<sub>11</sub></b>	<b>b<sub>22</sub></b>	<b>b<sub>12</sub></b>	<b>R<sup>2</sup></b>	<b>P</b>
<b>FM</b>	245.33	121	-322.33	13	277	-143.5	0.965	0.021 1
<b>p Value</b>	0.0535	0.068 7	0.005	0.8738	0.0347	0.0739	-	-
<b>RM</b>	254	-	-322.33	-	277	-	0.791	0.009 0




**Figure 10: Response surface plot for FLT (sec)**

**Full and reduced model for Diffusion exponent (n)**

$$Y1 = 0.585 + 0.029(X_1) - 0.043(X_2) + 0.008(X_1X_1) + 0.025(X_2X_2) - 0.006(X_1X_2)$$

**Summary of results of regression analysis for Diffusion exponent (n)**

Response n	b <sub>0</sub>	b <sub>1</sub>	b <sub>2</sub>	b <sub>11</sub>	b <sub>22</sub>	b <sub>12</sub>	R <sup>2</sup>	P
<b>FM</b>	0.585	0.029	-0.043	0.008	0.025	-0.006	0.976	0.0121
<b>p Value</b>	8.14E-06	0.0096	0.0031	0.4124	0.0566	0.3538	-	-
<b>RM</b>	0.608	0.029	-0.043	-	-	-	0.887	0.0014




**Figure 11: Response surface plot for n**

**Full and reduced model for Release rate constant (k)**

$$Y1 = 0.159 - 0.023 (X_1) + 0.056 (X_2) - 0.006 (X_1X_1) + 0.008 (X_2X_2) - 0.005 (X_1X_2)$$

**Summary of results of regression analysis for Release rate constant (k)**

<b>Response k</b>	<b>b<sub>0</sub></b>	<b>b<sub>1</sub></b>	<b>b<sub>2</sub></b>	<b>b<sub>11</sub></b>	<b>b<sub>22</sub></b>	<b>b<sub>12</sub></b>	<b>R<sup>2</sup></b>	<b>P</b>
<b>FM</b>	0.159	-0.023	0.056	-0.006	0.008	-0.005	0.995	0.0008
<b>p Value</b>	3.85E-05	0.0018	0.0001	0.1754	0.1080	0.1319	-	-
<b>RM</b>	0.161	-0.023	0.056	-	-	-	0.979	8.98E-06



**Figure 12: Response surface plot for k**

**Table 9: Kinetic treatment of dissolution data**

	<b>B1</b>	<b>B2</b>	<b>B3</b>	<b>B4</b>	<b>B5</b>	<b>B6</b>	<b>B7</b>	<b>B8</b>	<b>B9</b>
<b>Zero order</b>									
<b>S</b>	3.542	3.397	3.285	4.163	3.688	3.502	5.676	5.429	5.229
<b>I</b>	14.392	11.449	10.185	20.859	21.932	14.736	28.644	27.624	20.413
<b>R<sup>2</sup></b>	0.995	0.997	0.998	0.986	0.983	0.998	0.976	0.976	0.989
<b>First order</b>									
<b>S</b>	0.030	0.032	0.034	0.033	0.029	0.030	0.041	0.039	0.040
<b>I</b>	1.333	1.275	1.223	1.426	1.429	1.345	1.515	1.503	1.431
<b>R<sup>2</sup></b>	0.960	0.959	0.943	0.950	0.929	0.960	0.922	0.921	0.949
<b>Higuchi</b>									
<b>S</b>	22.161	21.141	20.382	24.237	23.037	21.754	28.627	28.208	28.274
<b>I</b>	-15.781	-17.116	-17.573	-10.164	-9.672	14.584	-3.615	-5.050	-13.349

<b>R<sup>2</sup></b>	0.990	0.987	0.993	0.993	0.996	0.986	0.997	0.997	0.995
<b>Hixon Crowell</b>									
<b>S</b>	-1.180	-1.132	-1.086	-1.388	-1.229	-1.167	-1.892	-1.810	-1.743
<b>I</b>	28.535	29.517	29.938	26.380	29.023	28.421	23.785	24.125	26.529
<b>R<sup>2</sup></b>	-0.995	-0.997	-0.998	-0.986	-0.983	-0.998	0.976	-0.976	-0.989
<b>Korsmeyer and Peppas</b>									
<b>n</b>	0.622	0.654	0.705	0.572	0.592	0.609	0.551	0.563	0.607
<b>I</b>	-0.898	-0.970	-1.051	-0.755	-0.798	-0.884	-0.609	-0.636	-0.732
<b>R<sup>2</sup></b>	0.988	0.992	0.998	0.988	0.997	0.994	0.998	0.998	0.996
<b>S= slope, I= intercept, R<sup>2</sup>= square of correlation coefficient, n= diffusion exponent</b>									

**Comparison of dissolution profiles for selection of optimum batch**

**Table 10: Similarity Factor ( $f_2$ ) and Dissimilarity factor ( $f_1$ ) for B1-B9**

<b>Batch</b>	<b>Similarity factor (<math>f_2</math>)</b>	<b>Dissimilarity factor (<math>f_1</math>)</b>
<b>B1</b>	71.52	5.95
<b>B2</b>	69.58	5.45
<b>B3</b>	58.81	9.78
<b>B4</b>	39.82	32.08
<b>B5</b>	45.53	21.35
<b>B6</b>	74.41	4.24
<b>B7</b>	23.61	89.53
<b>B8</b>	24.89	80.06
<b>B9</b>	30.23	56.07



**Table 11: Result of tablet parameter of Accelerated Stability Study**

<b>Parameter</b>	<b>Initial</b>	<b>After 21 day</b>
Hardness (kg/cm <sup>2</sup> )	6.7	6.8
Friability (%)	0.61	0.64
Floating lag time (sec)	267	273
Total floating time (hr)	>24	>24
Drug content (%)	99.89	99.76
similarity factor ( $f_2$ )	74.41	76.41
Dissimilarity factor ( $f_1$ )	4.24	3.86